das biotech start-up mit 1000% phantasie - 500 Beiträge pro Seite

[sagenhaft]

verfolgt mal diese company, sehr vielversprechend und mit grandiosen chancen versehen.. ein zock absolut wert, vielleicht auch mehr als das !!!


übrigens, wie kann es auch anders sein, gefunden bei SUNTRADE.DE


Investigational New Drug Application for Liprostin Filed With Food and Drug Administration

MONTGOMERY, Texas--(BUSINESS WIRE)--Oct. 3, 2000--Endovasc Ltd. Inc. (OTCBB:ENDV) today announced that it had submitted an Investigational New Drug application (IND) to the U.S. Food and Drug Administration (FDA) for Liprostin(TM), the Company`s liposomal encapsulated prostaglandin E-1 drug.

Liprostin will be tested in patients who have lost circulation in their lower limbs and are in critical danger of requiring amputation, a condition called critical limb ischemia (CLI).

Dr. David Summers, chairman and CEO of Endovasc, said, "This disease results in over 150,000 lower-limb amputations per year and at present there is no FDA approved pharmacotherapy. Amputation presents dismal prospects for a continued positive quality-of-life for these patients equal to cancer or other terminal illnesses. We intend to improve these prospects."

According to Jenna Tagliaferri, director of regulatory affairs for Endovasc, "We expect to begin Phase I human clinical trials approximately 30 days after this IND filing, contingent on any additional requests from the FDA prior to the commencement of trials."

Recruitment of patients for the trials has begun at the University of Texas Health Science Center-Hermann Hospital under the direction of Principal Investigator Dr. Richard Smalling, who reported at the Company`s recent Scientific Advisory Board meeting that, "Prostaglandin E-1 rapidly dissolves blood clots and apparently prevents white blood cells and platelets from sticking together. This should greatly improve the outcomes of these patients."

Ms. Tagliaferri also said that the Company will expand trials to other clinical sites in the U.S., and will also begin clinical trials in Europe within the next few months at the Polyclinique d`Essey-les-Nancy, France, under the direction of Michel Henry, M.D., an internationally noted cardiologist.

Although the FDA waived their requirement for Phase I and II trials in their November 1999 pre-IND meeting with Endovasc, the Company`s management and scientific team determined that implementation of modified Phase I and II trials will be critical in the rapid, efficient and decisive success of Phase III.

Endovasc Ltd. Inc. is a biopharmaceutical company pioneering liposomal drug delivery technology. The company`s products and processes are covered by patents and trade secrets for competing in a multi-billion dollar market.

The foregoing statements are made under the "Safe Harbor" Private Securities Litigation Reform Act of 1995 and may contain forward-looking statements that involve risks and uncertainties that may not be evident at the time of this release. For more information about Endovasc Ltd. Inc., contact:

[Batterie]

Ich dachte es geht um Sangui bei diesem Titel
http://finance.yahoo.com/q?s=SGBI.OB&d=t

Nun gut schaun wir uns mal ENDV an. Im ersten Augenblick nicht gerade Vertrauenserweckend. Markteng und seit etwa 4 Monaten in einem Abwärtstrendkanal. Aber wenn dieser verlassen wird dann sieht es wohl nicht schlecht aus.

[Clark-W.Griswaldt]

hatte ich auch vor kurzem zu 0,07$,nur für 1700E, gekauft aber dann nach ein paar tagen zu 15,00$ wieder verkauft

[sagenhaft]

hallo hallo !

hab das grad bei suntrade.de entdeckt ! man sollte wohl nahe dranbleiben denn mit dieser bühne wird wallstreet endv ins fokus nehmen ! spekualtive anleger sollten doppelclicken !

sagenhaft


Endovasc Ltd. Inc. Announces Airdate for
National Spotlight On Business World News`

MONTGOMERY, Texas--(BUSINESS WIRE)--Oct. 13, 2000--Endovasc Ltd.
Inc. (OTCBB:ENDV) announced that the company will air on "Business
World News" on The Learning Channel as sponsored programming on
Sunday, October 15, 2000 at 7:30 a.m. (check local listing).
Interviews and brief descriptions of the company`s research and
development work and upcoming clinical trials will highlight
Liprostin(TM), as well as the company`s newly licensed angiogenic
growth agent, nicotine receptor agonist (NRA).
If you have questions about the broadcast, please call Endovasc
Ltd. Inc. and not The Learning Channel.
The sponsored programming will be rebroadcast in major
metropolitan cities on national Cable Networks and/or broadcast
affiliates. Below is the October schedule:
-- October 21/8:30 p.m., Channel 31/AT&T in San Francisco
-- October 22 & 23/7:00 p.m., AT&T cable in Chicago
-- October 26/9:00 p.m., Channel 3/Charter Comm. in Riverside,
Calif.
-- October 30/6:30 p.m., Channel 23A/AT&T in San Jose, Calif.
"Business World News" is a nationally acclaimed syndicated TV news
magazine series which provides a behind-the-scenes look at innovative
and successful companies and the people that made them that way. It is
seen nationally on CBS and ABC affiliates, and major cable networks
(as sponsored programming) as well as on-board cruise lines and
airlines. The series is produced by TVA Productions, one of the
largest business television and video production studios on the West
Coast. TVA`s team has won over 40 Emmy, Clio, Telly and Aegis awards.
They are long-time members and judges for the Academy of Television
Arts & Sciences, National Association of Television Programming
Executives (NATPE), IAPPA and Themed Entertainment Association.
Companies do not pay a fee to be profiled on the Show, only for
the commercial use of their Spotlight. Any information provided on the
Show or via press release is provided strictly as the opinion of the
Show`s producers who may also be shareholders and is not intended as
an attempt to sell securities or provide financial advise.
Endovasc Ltd. Inc. is a biopharmaceutical company pioneering
liposomal drug delivery technology. The company`s products and
processes are covered by patents and trade secrets for competing in a
multi-billion dollar market. In February 2000, the company obtained
worldwide exclusive license for a newly discovered angiogenesis agent,
nicotine receptor agonist (NRA), a potent "angiogenic" growth agent
that stimulates the growth of new blood vessels in strategic areas of
the body. The company stated that the study could be started before
the end of the year.
The foregoing statements are made under the "Safe Harbor" Private
Securities Litigation Reform Act of 1995 and may contain
forward-looking statements that involve risks and uncertainties that
may not be evident at the time of this

[sagenhaft]

ich glaube es einfach nicht.. was ist falsch an ednv ?? schaut euch die news da unten an..gefunden bei suntrade.de

achtung extrem marktenger wert !!!! nicht kaufen !!oder streng limitiert !!!!!



Endovasc Files Two New Pioneer Patents Large
Market Anticipated

MONTGOMERY, Texas--(BUSINESS WIRE)--Oct. 11, 2000--Endovasc Ltd.
Inc. (OTCBB:ENDV) announced today the filing of: Method and Apparatus
for Treating Vascular Disease with PGE-1 Bearing Liposomes, which was
assigned U.S. Patent Application Serial No. 08/867,189 and Method and
Apparatus for Treating a Cancer with a Totally Resorbable
Biodegradable Stent (no serial number assigned as yet).
Dr. Diane Dottavio, director of research and development, said,
"The patent was filed several years ago as a provisional patent
application and has the potential for reviving `plain ole angioplasty`
(POB) procedures in lieu of stents since the liposomes are deposited
through the outer luminal barrier and into the media where they block
smooth muscle migration and white cell recruitment."
The second application is further intellectual protection (IP) of
U.S. Patent 5,980,551 issued Nov. 9, 1999, that is being used as the
basis in various ongoing collaborative developments with the company.
The patent covers the placement of cancer drugs in a biodegradable
stent that is totally resorbed by the body in 6-10 months. "This
method of drug treatment provides the ability of the physician to
treat tumors with very high local levels of drugs directly at the
tumor while greatly lowering the systemic drug effect over the rest of
the body," said Dr. Dottavio.
Endovasc Ltd. Inc. is a biopharmaceutical company pioneering
liposomal and stent drug delivery technology. The company`s products
and processes are covered by patents and trade secrets for competing
in a multi-billion dollar market. The company expects biodegradable
stents to capture a 50% share of the $1 billion stent market within
two years from approval.
The foregoing statements are made under the "Safe Harbor" Private
Securities Litigation Reform Act of 1995 and may contain
forward-looking statements that involve risks and uncertainties that
may not be evident at the time of this release. For more information
about Endovasc Ltd. Inc., contact:
--30--HM/ho*
CONTACT: Endovasc Ltd. Inc., Montgomery
Barbara Richardson, 936/448-2222
Fax: [phone]
[e-mail]
www.endovasc.com
or
The Dilenschneider Group Inc., New York
Dick Kosmicki, 212/922-0900
[e-mail]
Fax: [phone]
or

[sagenhaft]

hallo,

bei suntrade wieder mal was gefunden zu endv !

durch nationale bekanntheit sollte auch der kurs profitiern.


Endovasc Ltd. Inc. Announces October Airdate
for National Spotlight On Business World News`

MONTGOMERY, Texas--(BUSINESS WIRE)--Oct. 16, 2000--Endovasc Ltd.
Inc. (OTCBB:ENDV) announced that the company will air on "Business
World News" as sponsored programming on national Cable Networks and/or
broadcast affiliates in major metropolitan cities. Below is the
October schedule:
-- October 21/8:30 p.m., Channel 31/AT&T in San Francisco
-- October 22 & 23/7:00 p.m., AT&T cable in Chicago
-- October 26/9:00 p.m., Channel 3/Charter Comm. in Riverside,
Calif.
-- October 30/6:30 p.m., Channel 23A/AT&T in San Jose, Calif.
Interviews and brief descriptions of the company`s research and
development work and upcoming clinical trials will highlight
Liprostin(TM), as well as the company`s newly licensed angiogenic
growth agent, nicotine receptor agonist (NRA). The first sponsored
programming was aired on The Learning Channel on Sunday, October 15,
2000 at 7:30 a.m.
"Business World News" is a nationally acclaimed syndicated TV news
magazine series which provides a behind-the-scenes look at innovative
and successful companies and the people that made them that way. It is
seen nationally on CBS and ABC affiliates, and major cable networks
(as sponsored programming) as well as on-board cruise lines and
airlines. The series is produced by TVA Productions, one of the
largest business television and video production studios on the West
Coast. TVA`s team has won over 40 Emmy, Clio, Telly and Aegis awards.
They are long-time members and judges for the Academy of Television
Arts & Sciences, National Association of Television Programming
Executives (NATPE), IAPPA and Themed Entertainment Association.
Companies do not pay a fee to be profiled on the Show, only for
the commercial use of their Spotlight. Any information provided on the
Show or via press release is provided strictly as the opinion of the
Show`s producers who may also be shareholders and is not intended as
an attempt to sell securities or provide financial advise.
Endovasc Ltd. Inc. is a biopharmaceutical company pioneering
liposomal drug delivery technology. The company`s products and
processes are covered by patents and trade secrets for competing in a
multi-billion dollar market. In February 2000, the company obtained
worldwide exclusive license for a newly discovered angiogenesis agent,
nicotine receptor agonist (NRA), a potent "angiogenic" growth agent
that stimulates the growth of new blood vessels in strategic areas of
the body. The company stated that the study could be started before
the end of the year.
The foregoing statements are made under the "Safe Harbor" Private
Securities Litigation Reform Act of 1995 and may contain
forward-looking statements that involve risks and uncertainties that
may not be evident at the time of this release. For more information
about Endovasc Ltd. Inc., contact:
--30--BMD/ho*
CONTACT: Endovasc

[CYSONIC]

Hello my friends!

Habt ihr euch mal die Biotechliste "Oeration Starperformer" bei SUNTRADE angesehen? Hab` mir mal ein paar Werte davon gekauft...

Greetingz
CYSONIC

[sagenhaft]

ja war auch dort, neben der neuen trading box und der gratis hotline gefällt mir dies auch sehr gut

[TradingDestination]

Echt geniale Idee die neue Tradingbox, habt ihr schon die heutigen Werte von dort recherchiert? Ich bin gespannt, wie die sich entwickeln!
TD

[ricox]

Wo soll dort diese mysterische Liste sein?

[Aber Hallo]

Wann werden diese Werbeheinis endlich gesperrt?

[sagenhaft]

hallo leute !

endovasc kommt an der discovery expo am montag zum zug !!

dies wird die öffentlichkeit auf ENDV aufmerksam machen ..

also seid bereit auf und achtet auf die volumen

achtung sehr marktenger wert !!

bis dann

sagenhaft

aber hallo ?? was hast du für ein problem ? hier gehts um endovasc und das ist keine werbung quellen angaben und neue produkte auf konkurrenz seiten stört wohl niemanden oder ?

[menatwork00]

Hallo sagenhaft,

hast du die Möglichkeit deine Treads ins Deutsche zu übersetzen.

Weißt du, ob und wann Endovasc aus dem Freiverkehr-Handel aufsteigt,
gibt es da irgendwelche Planungen. Da sind ja Kursschwankungen dabei
wie bei der Achterbahn-aber ich mag solche Werte. *grins*

Gruß MH

[menatwork00]

Ok sagenhaft,

habe deine englischen Tread´s übersetzt-ok da wird ja ab heute kräftig
die Werbetrommel gedreht-Hoffe doch sehr das TV und Messe( ab heute ) etwas bewirken damit auch andere auf diesen Wert aufmerksam werden. Habe mich ein wenig schlau gemacht. Nicht jeder wird zu dieser Messe (Discovery Expo 2000) eingeladen in New York. Aber seht euch den Text selber an habe ihn hier reingestellt.

War etwas schwierig zu ordern-habe aber comdirect die WKN benannt-jetzt dürfte es kein Problem mehr sein. Die hatte keine WKN zu diesem
Wert :-)))

W K N an der OTC New York 919591

Habe mir selber einige zugelegt. Das dieses ein absoluter Zockerwert ist, brauch ich wohl nicht zu erwähnen-bitte streng limitieren.

Jede Firma hofft durch diese Messe einen großen Bekanntheitsgrad zu erlangen um später aus dem OTC Freiverkehr heraus in die Nasdaq zu gelangen-und da denke ich, das diese eine große Chance ist für diesen
Wert. Was das bedeutet aus dem Freihandel raus / Nasdag rein-brauch ich hier wohl in Sachen Kurssprünge wohl nicht zu erklären.

Gruß MH


ENDOVASC LTD., INC. TO BE ONE OF 70 COMPANIES WORLDWIDE TO PARICIPATE IN
DISCOVERY EXPO 2000, OCTOBER 23RD, IN NEW YORK CITY

Montgomery, Texas - Endovasc Ltd. Inc. (OTC BB:ENDV) will be among 70 of the
top growth companies in the world to gather October 23rd at Discovery Expo
2000 to meet financial movers and shakers at the Hilton New York.

The Expo brings together underdiscovered companies with high-profile growth
fund managers, analysts, stockbrokers and sophisticated investors in a
one-day event. These key players will have a chance to become acquainted
with the products, top executives and future outlook of participating Nasdaq
and OTC Bulletin Board listed firms whose stock represents opportunities for
appreciation.

This fourteenth in a unique series of Discovery Expos was organized by The
Investment Reporter.

"When you`re a mid-cap or small-cap company you tend to fall off the
financial radar screen no matter how well you`re doing financially," said
John G. Robbins, publisher of The Investment Reporter, a Newport Beach,
CA-based financial newspaper. "The financial world needs to find growing
companies whose shares have further upside potential and these companies
want to be discovered. Discovery Expo 2000 is a convenient way for them to
find each other."

Dwight Cantrell, Chief Financial Officer for Endovasc, commented that, "We
look forward to again participating in the Discovery Expo and the
opportunity to spotlight the company, its projects, and growth potential."

See the company profiles on www.emergingequities.com.

Endovasc Ltd., Inc. is a biopharmaceutical company pioneering liposomal drug
delivery technology. The company`s products and processes are covered by
patents and trade secrets for competing in a multi-billion market. In
February 2000, the company obtained worldwide exclusive license for a newly
discovered angiogenesis agent, nicotine receptor agonist (NRA), a potent
"angiogenic" growth agent that stimulates the growth of new blood vessels in
strategic areas of the body.

[sagenhaft]

expo in new york war ein voller erfolg !

dranbleiben !!

[menatwork00]

Hallo sagenhaft,

es befinden sich zwei treads zu endovasc auf diesem board-schau mal vorbei. Das mit New york ist klasse.

Gib bitte Endovasc als Suchbegriff oben links bei der Boardübersicht ein.

Gruß MH